Searched for
SPIRIVA
Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...- Pharma and healthcare companies to face continued margin pressure: HDFC SecuritiesThe Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the Marc...
- Lupin shares jump 6% after Kotak Equities’ double upgrade, target price at Rs 1,805Kotak Equities highlights that Lupin has a bunch of products lined up, which will ensure a limited earnings dip in FY2027E after a strong F...
- 2 top stock picks from Foram Parekh for near termSo, now 31% margin for Divi’s is a good thing as against the lower margin what it used to clock. And going forward, this kind of margins ar...
- Foram Parekh on what to bet on in pharma packForam Parekh shares insights on CDMO companies' positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about L...
- Hot Stocks: Brokerage view on Page Industries, Zomato, Lupin and ITCMacquarie maintained an underperform rating on Zomato with a target price of Rs 76. The company has seen steady margin improvements and str...
- Just coming to our own in India; confident of growing our US business in next fiscal year: Lupin managementLupin's margin guidance remains around 19.5-20.5%. The company attributes its success to the pivot to complex products, cost-led initiative...
- Fundamental Radar: Sales of this single drug can take Lupin’s US revenue to $1 billion in FY-26Lupin's focus on the US portfolio is to increase dollar sales to above $200 million from the earlier range of $170-190 million. Lupin recen...
- Lupin to acquire established products in Europe, Canada from Sanofi for Rs 91 crLupin has acquired a portfolio of established products in Europe and Canada from Sanofi for a purchase consideration of EUR 10 million. The...
- Hot Stocks: Brokerage view on Delhivery, Bank of Baroda, Lupin, SBI and M&MDelhivery can sustain strong 18-20% revenue CAGR for a long period of time. Over the medium term, the brokerage firm sees adjusted EBIT mar...
- Lupin shares fall over 4%. Should you buy, sell or hold? Here's what brokerages sayLupin witnessed a fall of over 4% to Rs 838.1 in intra-day trade on BSE after brokerages such as Jefferies, Kotak, and Bernstein maintained...
- Hot Stocks: Brokerages on Shriram Finance, Paradeep Phosphates, L&T and LupinJefferies upgraded Shriram Finance to "buy" and retained a "buy" rating on L&T while Antique initiated a "buy" on Paradeep Phosphates. Kota...
- Hot Stocks: Brokerages on HPCL, Manappuram Finance, Dr Lal Pathlabs and LupinJefferies maintained an underperform rating on Hindustan Petroleum Corporation Limited (HPCL) citing weak marketing and transitory refining...
- Analysts bearish on 'expensive' Lupin after Q3 disappoints, stock falls 9%Of the 44 analysts, 18 of them have a 'sell' rating while 15 remain neutral. On aggregate, analysts slashed consensus price targets by 4.35...
- Lupin's arm gets UK regulator nod for COPD treatmentGlobal pharma major Lupin Limited on Friday announced that its UK subsidiary, Lupin Healthcare (UK) Limited, has received approval from the...
- Sell Lupin, target price Rs 575: JM FinancialLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 31616.79 Crore) operating in Pharmaceuticals s...
- Buy Lupin, target price Rs 1100: Emkay GlobalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 36549.22 Crore) operating in Pharmaceuticals s...
- Glenmark Pharma launches COPD treatment inhaler in UKDrug firm Glenmark Pharma on Tuesday announced the launch of Tiotropium Bromide Dry Powder Inhaler, used in the treatment of chronic obstru...
- Lupin gains 3% on Credit Suisse upgrade, Nomura’s buy ratingNomura has maintained a ‘buy’ rating on Lupin with a target price of Rs 1,017.
- Glenmark inks licensing pact for generic Tiotropium Bromide dry powder inhaler in Western EuropeThis is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler, the ...
Load More
